Histone lysine methyltransferases as anti-cancer targets for drug discovery

被引:0
|
作者
Qing Liu
Ming-wei Wang
机构
[1] The CAS Key Laboratory of Receptor Research,
[2] Shanghai Institute of Materia Medica,undefined
[3] Chinese Academy of Sciences,undefined
[4] The National Center for Drug Screening,undefined
[5] School of Pharmacy,undefined
[6] Fudan University,undefined
来源
Acta Pharmacologica Sinica | 2016年 / 37卷
关键词
histone methyltransferases; adenosylmethionine; small molecule inhibitors; anti-cancer drugs; epigenetic modification; drug discovery;
D O I
暂无
中图分类号
学科分类号
摘要
Post-translational epigenetic modification of histones is controlled by a number of histone-modifying enzymes. Such modification regulates the accessibility of DNA and the subsequent expression or silencing of a gene. Human histone methyltransferases (HMTs)constitute a large family that includes histone lysine methyltransferases (HKMTs) and histone/protein arginine methyltransferases (PRMTs). There is increasing evidence showing a correlation between HKMTs and cancer pathogenesis. Here, we present an overview of representative HKMTs, including their biological and biochemical properties as well as the profiles of small molecule inhibitors for a comprehensive understanding of HKMTs in drug discovery.
引用
收藏
页码:1273 / 1280
页数:7
相关论文
共 50 条
  • [1] Histone lysine methyltransferases as anti-cancer targets for drug discovery
    Liu, Qing
    Wang, Ming-wei
    ACTA PHARMACOLOGICA SINICA, 2016, 37 (10) : 1273 - 1280
  • [2] Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
    Zhao, Hongyu
    Wang, Ying
    Li, Huanqiu
    CURRENT MEDICINAL CHEMISTRY, 2015, 22 (17) : 2075 - 2086
  • [3] Mapping of mTOR drug targets: Featured platforms for anti-cancer drug discovery
    Shams, Raef
    Ito, Yoshihiro
    Miyatake, Hideyuki
    PHARMACOLOGY & THERAPEUTICS, 2022, 232
  • [4] Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug Discovery
    Ganesan, A.
    Nolan, L.
    Crabb, S. J.
    Packham, G.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (08) : 963 - 981
  • [5] Unsafe SETs: histone lysine methyltransferases and cancer
    Schneider, R
    Bannister, AJ
    Kouzarides, T
    TRENDS IN BIOCHEMICAL SCIENCES, 2002, 27 (08) : 396 - 402
  • [6] Targets of histone H3 lysine 9 methyltransferases
    Levinsky, Aidan J.
    McEdwards, Gregor
    Sethna, Nasha
    Currie, Mark A.
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [7] Lysine Ethylation by Histone Lysine Methyltransferases
    Al Temimi, Abbas H. K.
    Martin, Michael
    Meng, Qingxi
    Lenstra, Danny C.
    Qian, Ping
    Guo, Hong
    Weinhold, Elmar
    Mecinovic, Jasmin
    CHEMBIOCHEM, 2020, 21 (03) : 392 - 400
  • [8] GPCRs: Emerging anti-cancer drug targets
    Gutierrez, Ainhoa Nieto
    McDonald, Patricia H.
    CELLULAR SIGNALLING, 2017, 41 : 65 - 74
  • [9] Atropisomerism transforming anti-cancer drug discovery
    Patel, Simran
    Sandha, Khushi
    Waingankar, Anushka
    Jain, Prachi
    Abhyankar, Arundhati
    CHEMICAL BIOLOGY & DRUG DESIGN, 2023, 101 (01) : 138 - 157
  • [10] Bioinformatics Approaches for Anti-cancer Drug Discovery
    Li, Kening
    Du, Yuxin
    Li, Lu
    Wei, Dong-Qing
    CURRENT DRUG TARGETS, 2020, 21 (01) : 3 - 17